BIOFERMIN PHARMACEUTICAL CO LTD has a total of 26 patent applications. It increased the IP activity by 250.0%. Its first patent ever was published in 2001. It filed its patents most often in WIPO (World Intellectual Property Organization), Taiwan and China. Its main competitors in its focus markets pharmaceuticals, foods and drinks and biotechnology are PHARMA NORD APS, HOUSE WELLNESS FOODS CORP and SEQUOIA SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 7 | |
#2 | Taiwan | 5 | |
#3 | China | 4 | |
#4 | United States | 3 | |
#5 | Singapore | 2 | |
#6 | Brazil | 1 | |
#7 | Canada | 1 | |
#8 | EPO (European Patent Office) | 1 | |
#9 | Mexico | 1 | |
#10 | Philippines | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Foods and drinks | |
#3 | Biotechnology | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Foods | |
#4 | Microorganisms | |
#5 | Microorganisms | |
#6 | Specific use of cosmetics | |
#7 | Heterocyclic compounds | |
#8 | Special foods | |
#9 | Acyclic or carbocyclic compounds | |
#10 | Fodder |
# | Name | Total Patents |
---|---|---|
#1 | Ohno Hiroshi | 20 |
#2 | Shimakawa Masaki | 20 |
#3 | Tanaka Yoshiki | 16 |
#4 | Oikawa Yosuke | 9 |
#5 | Maeda Ayako | 7 |
#6 | Kawahara Tomohiro | 5 |
#7 | Kessoku Takaomi | 4 |
#8 | Nakajima Atsushi | 4 |
#9 | Isa Yasuhiro | 3 |
#10 | Yamamura Hideki | 3 |
Publication | Filing date | Title |
---|---|---|
WO2021079869A1 | Uremic toxin reducing agent | |
US2020338144A1 | Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor | |
WO2019087841A1 | AGENT FOR PREVENTING OR TREATING SMALL INTESTINAL DISORDER INDUCED BY CERTAIN NSAIDs AND PPI | |
CN111107860A | Prophylactic or therapeutic agent for fat-related disease and/or inflammation | |
US2019262408A1 | Agent acting on transcellular ion transporter in intestinal tract, agent for activating chloride channel, agent for preventing or treating renal disease, or agent for promoting defecation | |
WO2012011174A1 | Lipid metabolism improving agent, agent for enhancing lipid metabolism improving action, anti-obesity agent, and agent for enhancing anti-obesity action | |
SG10201400931RA | Agent for enhancing hypoglycemic activity |